RMA
CAPR icon

Roffman Miller Associates’s Capricor Therapeutics CAPR Stock Holding History

Roffman Miller Associates’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500
Closed -$2.39K – 96
2023
Q2 		$2.39K Buy
+500
New +$2.2K ﹤0.01% 138

Other funds holding CAPR

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Roffman Miller Associates's CAPR Position: Q3 2023 in Review

Roffman Miller Associates sold out of Capricor Therapeutics (CAPR) in Q3 2023, closing a stake of 500 shares — an estimated $2.39K sold.

Roffman Miller Associates first reported a position in CAPR in Q2 2023 and held it in 1 quarter. The position peaked at $2.39K in Q2 2023. 34 funds tracked by Wall St. Rank hold CAPR as of Q3 2023.

  • Roffman Miller Associates reported no remaining Capricor Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Roffman Miller Associates sold 500 Capricor Therapeutics shares in Q3 2023, an estimated $2.39K.
  • Roffman Miller Associates first reported a position in Capricor Therapeutics in Q2 2023 and held it in 1 quarter.
  • Roffman Miller Associates's Capricor Therapeutics position peaked at $2.39K in Q2 2023.
  • 34 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2023.

Based on Roffman Miller Associates's 13F filing for Q3 2023, filed 9 Nov 2023.